Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(03): 311-313
DOI: 10.1055/s-0042-1743504
Brief Communication

Case for More Autologous Transplants in Myeloma in Resource-Constrained Settings

Suvir Singh 
1   Department of Clinical Hematology and Stem Cell Transplantation, Dayanand Medical College, Ludhiana, Punjab, India
,
Rintu Sharma
1   Department of Clinical Hematology and Stem Cell Transplantation, Dayanand Medical College, Ludhiana, Punjab, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Multiple myeloma is characterized by a near universal risk of relapse. Autologous stem cell transplantation provides a significant progression free survival benefit but is under utilized worldwide. We provide a small snapshot of why ASCT assumes greater importance in resource-constrained settings.

Keywords

hematology - medical oncology - myeloma - transplant


Publication History

Article published online:
28 June 2022

© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Björkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007; 25 (15) 1993-1999
    CrossrefPubMedGoogle Scholar
  • 2 Usui Y, Ito H, Koyanagi Y. et al. Changing trend in mortality rate of multiple myeloma after introduction of novel agents: a population-based study. Int J Cancer 2020; 147 (11) 3102-3109
    CrossrefPubMedGoogle Scholar
  • 3 Dimopoulos MA, Moreau P, Terpos E. et al; EHA Guidelines Committee. Electronic address: guidelines@ehaweb.org, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up† . Ann Oncol 2021; 32 (03) 309-322
    CrossrefPubMedGoogle Scholar
  • 4 Moreau P, Touzeau C. Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation. Leuk Suppl 2013; 2 (Suppl. 01) S15-S20
    CrossrefPubMedGoogle Scholar
  • 5 Mateos M-V, Cavo M, Blade J. et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 2020; 395 (10218): 132-141
    CrossrefPubMedGoogle Scholar
  • 6 Kumar S, Jacobus SJ, Cohen AD. et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): results of ENDURANCE (E1A11) phase III trial. J Clin Oncol 2020; 38 (18) 3
    CrossrefGoogle Scholar
  • 7 Facon T, Kumar S, Plesner T. et al; MAIA Trial Investigators. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019; 380 (22) 2104-2115
    Google Scholar
  • 8 Gay F, Cerrato C, Petrucci MT. et al. Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial. J Clin Oncol 2019; 37 (15) 8002-8002
    CrossrefGoogle Scholar
  • 9 Attal M, Lauwers-Cances V, Hulin C. et al; IFM 2009 Study. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 2017; 376 (14) 1311-1320
    CrossrefPubMedGoogle Scholar
  • 10 Cavo M, Petrucci MT, Di Raimondo F. et al. Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02/HO95 MM Trial). American Society of Hematology; Washington, DC: 2016
    Google Scholar
  • 11 Su B, Zhu X, Jiang Y. et al. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents. Leuk Lymphoma 2019; 60 (06) 1381-1388
    CrossrefPubMedGoogle Scholar
  • 12 Dhakal B, Szabo A, Chhabra S. et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol 2018; 4 (03) 343-350
    CrossrefPubMedGoogle Scholar
  • 13 Gonsalves WI, Buadi FK, Ailawadhi S. et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant 2019; 54 (03) 353-367
    CrossrefPubMedGoogle Scholar
  • 14 Costa LJ, Zhang M-J, Zhong X. et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant 2013; 19 (11) 1615-1624
    CrossrefPubMedGoogle Scholar
  • 15 Cowan AJ, Baldomero H, Atsuta Y. et al. The global state of hematopoietic stem cell transplantation for multiple myeloma: an analysis of the worldwide network of blood and marrow transplantation (WBMT) database and the Global Burden of Disease Study. Biol Blood Marrow Transplant 2020; 26 (12) 2372-2377
    CrossrefPubMedGoogle Scholar
  • 16 Kulkarni U, Devasia AJ, Korula A. et al. Clinical outcomes in multiple myeloma post-autologous transplantation-a single centre experience. Indian J Hematol Blood Transfus 2019; 35 (02) 215-222
    CrossrefPubMedGoogle Scholar
  • 17 Cowan AJ, Allen C, Barac A. et al. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol 2018; 4 (09) 1221-1227
    CrossrefPubMedGoogle Scholar
  • 18 Prinja S, Kaur G, Malhotra P. et al. Cost-effectiveness of autologous stem cell treatment as compared to conventional chemotherapy for treatment of multiple myeloma in India. Indian J Hematol Blood Transfus 2017; 33 (01) 31-40
    CrossrefPubMedGoogle Scholar
  • 19 Martino M, Paviglianiti A, Memoli M, Martinelli G, Cerchione C. Multiple myeloma outpatient transplant program in the era of novel agents: state-of-the-art. Front Oncol 2020; 10: 592487
    CrossrefPubMedGoogle Scholar